In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol

In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol

Sorafenib (SR) is one of the most potent UGT (1A1, 1A9) inhibitors (in in vitro tests). The inhibition of UGT1A1 may cause hyperbilirubinaemia, whereas the inhibition of UGT1A9 and 1A1 may result in drug-drug interactions (DDIs). Tapentadol (TAP) is a synthetic μ-opioid agonist and is used to treat...

Full description

Bibliographic Details
Main Authors: Agnieszka Karbownik, Miłosz Miedziaszczyk, Tomasz Grabowski, Joanna Stanisławiak-Rudowicz, Radosław Jaźwiec, Anna Wolc, Edmund Grześkowiak, Edyta Szałek
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Sorafenib
Sorafenib N-oxide
Tapentadol
Tapentadol glucuronide
Pharmacokinetics
Drug-drug interaction
Online Access:http://www.sciencedirect.com/science/article/pii/S075333222030723X

Internet

http://www.sciencedirect.com/science/article/pii/S075333222030723X

Similar Items